Getinge AB B

Getinge is engaged in three business areas: Medical Systems, Extended Care and Infection Control. Medical System's product range includes surgical tables, surgical lamps, telemedicine, perfusion products, instruments for bypass operations, ventilators, anesthesia systems, synthetic vascular implants and stents. Extended Care's product range includes bathing and shower solutions, lifting equipment and mattresses for the treatment and prevention of pressure ulcers, as well as service and consulting. Infection Control's product range comprises disinfectors, sterilizers, information technology systems and related equipment, as well as service and consulting.
  • TickerGETI B
  • ISINSE0000202624
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Christer Magnergård ...
  • Eivind Sars Veddeng
  • Frank Maaø
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Marius Knudssøn
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Northern Lights

Aksel Øverland Engebakken ...
  • Anders Idborg
  • Bengt Jonassen
  • John Olaisen
  • Martin Melbye
  • Olof Cederholm
  • Tobias Kaj
  • Victor Forssell

Talking Points - Equinor (Buy): Q3 likely to be soft

Sandvik (Hold) Post-results comment: SEK and charges boost resilience Our EBIT of USD 2.5bn is below FactSet of USD 2.8bn Still a BUY, but TP down to NOK 200 (210)

Nurhayati Wan

Getinge AB

Nurhayati Wan

Getinge AB

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Getinge - Strong Q3 with improved margins

Org. growth +4.8%, adj. EBITA margin +190bp vs ABGSC Positive revisions for ‘19e-‘21e Stick with HOLD – TP up to SEK 141 (125)

Aksel Øverland Engebakken ...
  • Anders Idborg
  • Bengt Jonassen
  • John Olaisen
  • Martin Melbye
  • Olof Cederholm
  • Tobias Kaj
  • Victor Forssell

Talking Points - Equinor (Buy): Q3 likely to be soft

Sandvik (Hold) Post-results comment: SEK and charges boost resilience Our EBIT of USD 2.5bn is below FactSet of USD 2.8bn Still a BUY, but TP down to NOK 200 (210)

Nurhayati Wan

Getinge AB

Nurhayati Wan

Getinge AB

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Getinge - Strong Q3 with improved margins

Org. growth +4.8%, adj. EBITA margin +190bp vs ABGSC Positive revisions for ‘19e-‘21e Stick with HOLD – TP up to SEK 141 (125)

Patrik Ling

Getinge (Buy, TP: SEK180.00) - Solid earnings beat

Getinge reported a solid Q3 earnings beat and was rewarded with a strong share price gain of c16%. The company was clear that 2019 is a transition year and the EBITA margin should continue to improve in the coming years. We believe the beat increased investors’ confidence that Getinge is moving in the right direction and the share price reaction should be seen in that light. We reiterate our BUY and have raised our target price to SEK180 (165) on increased earnings estimates.

1 director bought

A director at Getinge Ab bought 26,509 shares at 81.830SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Christer Magnergård ...
  • Eivind Sars Veddeng
  • Frank Maaø
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Marius Knudssøn
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Northern Lights

Alexander Aukner ...
  • Joachim Gunell
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Håkon Astrup
  • Jon Berggren
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Weak report across the board

Eivind Sars Veddeng ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Mattias Holmberg
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Stefan Gauffin

Nothern Lights

Håkon Astrup ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Stefan Gauffin

Northern Lights

GETINGE AB sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of GETINGE AB (SE), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date September 24, 2019, the closing price was SEK 144.45 and its potential was estimated at SEK 166.80.

Nurhayati Wan
Nurhayati Wan
Nurhayati Wan
Nurhayati Wan
MarketLine Department

Hill-Rom Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Hill-Rom Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Hill-Rom Holdings, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive adv...

GlobalData Department

Getinge AB (GETI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Getinge AB (Getinge) is a medical technology company that designs, develops and markets equipment and instruments in the areas of surgery, infection control, intensive care, care ergonomics and wound care. Its major products include surgical tables, lights, ventilators and anesthesia equipment, heart-lung machines with accompanying disposables, equipment and instruments for cardiac surgery, vascular surgery; cardiac assist devices; patient lifting devices, hospital beds, stretchers and couches, mattresses for treating and preventing pressure sores, disinfectors, sterilization equipmen...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/12/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting.Under ITEM 7, the board of directors seeks approval to distribute all shares in the wholly-owned subsidiary Arjo to the Company's shareholders. ECGS endorses the view of the board of directors that the proposal to split the Company into two separate listed companies (Getinge and Arjo) could enhance the prerequisites to succesfully develop the respective businesses. In addition, ECGS is generally supportive towards corporate spin-offs as they give s...

Expert Corporate Governance Service (ECGS)

Etude l' AG du 15/08/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting. Under ITEM 7, it is proposed to add a conversion clause, providing the opportunity to convert series A shares into series B shares, to the Company's Articles of Association. As a matter of principle, we welcome the addition of such a conversion clause. The clause is intended to facilitate the spin-off of the Company's Acute Care Therapies business ("Arjo") to its shareholders. Under the Swedish Companies Act conversion is only possible on a 1:1 basi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch